199 related articles for article (PubMed ID: 28159621)
21. Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases.
Longhena F; Spano P; Bellucci A
Handb Exp Pharmacol; 2018; 245():85-110. PubMed ID: 28965171
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.
Llorens F; Schmitz M; Varges D; Kruse N; Gotzmann N; Gmitterová K; Mollenhauer B; Zerr I
J Neurol; 2016 Nov; 263(11):2271-2277. PubMed ID: 27544498
[TBL] [Abstract][Full Text] [Related]
23. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Lee MK; Stirling W; Xu Y; Xu X; Qui D; Mandir AS; Dawson TM; Copeland NG; Jenkins NA; Price DL
Proc Natl Acad Sci U S A; 2002 Jun; 99(13):8968-73. PubMed ID: 12084935
[TBL] [Abstract][Full Text] [Related]
24. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
25. Baicalein inhibits formation of α-synuclein oligomers within living cells and prevents Aβ peptide fibrillation and oligomerisation.
Lu JH; Ardah MT; Durairajan SS; Liu LF; Xie LX; Fong WF; Hasan MY; Huang JD; El-Agnaf OM; Li M
Chembiochem; 2011 Mar; 12(4):615-24. PubMed ID: 21271629
[TBL] [Abstract][Full Text] [Related]
26. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.
Trojanowski JQ; Goedert M; Iwatsubo T; Lee VM
Cell Death Differ; 1998 Oct; 5(10):832-7. PubMed ID: 10203692
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 4-aminoindole carboxamide derivatives to curtail alpha-synuclein and tau isoform 2N4R oligomer formation.
Ramirez E; Min S; Ganegamage SK; Shimanaka K; Sosa MG; Dettmer U; Rochet JC; Fortin JS
Results Chem; 2023 Jan; 5():. PubMed ID: 37346091
[TBL] [Abstract][Full Text] [Related]
28. Alpha-synuclein: normal function and role in neurodegenerative diseases.
Norris EH; Giasson BI; Lee VM
Curr Top Dev Biol; 2004; 60():17-54. PubMed ID: 15094295
[TBL] [Abstract][Full Text] [Related]
29. Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases.
Nayak A; Salt G; Verma SK; Kishore U
Int Rev Neurobiol; 2015; 121():59-86. PubMed ID: 26315762
[TBL] [Abstract][Full Text] [Related]
30. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
Krüger R; Müller T; Riess O
J Neural Transm (Vienna); 2000; 107(1):31-40. PubMed ID: 10809401
[TBL] [Abstract][Full Text] [Related]
31. [Pathology of basal ganglia in neurodegenerative diseases].
Wakabayashi K; Tanji K; Mori F
Brain Nerve; 2009 Apr; 61(4):429-39. PubMed ID: 19378813
[TBL] [Abstract][Full Text] [Related]
32. Alpha-synuclein, Abeta and Alzheimer's disease.
Wirths O; Bayer TA
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):103-8. PubMed ID: 12551731
[TBL] [Abstract][Full Text] [Related]
33. Differential calcium alterations in animal models of neurodegenerative disease: Reversal by FK506.
Overk CR; Rockenstein E; Florio J; Cheng Q; Masliah E
Neuroscience; 2015 Dec; 310():549-60. PubMed ID: 26341908
[TBL] [Abstract][Full Text] [Related]
34. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases.
Melki R
J Parkinsons Dis; 2015; 5(2):217-27. PubMed ID: 25757830
[TBL] [Abstract][Full Text] [Related]
35. Neuropathological correlates of cerebral multimorbidity.
Attems J; Jellinger K
Curr Alzheimer Res; 2013 Jul; 10(6):569-77. PubMed ID: 23627751
[TBL] [Abstract][Full Text] [Related]
36. Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses.
Wilkaniec A; Czapski GA; Adamczyk A
J Neurochem; 2016 Jan; 136(2):222-33. PubMed ID: 26376455
[TBL] [Abstract][Full Text] [Related]
37. Synphilin in normal human brains and in synucleinopathies: studies with new antibodies.
Murray IJ; Medford MA; Guan HP; Rueter SM; Trojanowski JQ; Lee VM
Acta Neuropathol; 2003 Feb; 105(2):177-84. PubMed ID: 12536229
[TBL] [Abstract][Full Text] [Related]
38. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration.
Tsika E; Moysidou M; Guo J; Cushman M; Gannon P; Sandaltzopoulos R; Giasson BI; Krainc D; Ischiropoulos H; Mazzulli JR
J Neurosci; 2010 Mar; 30(9):3409-18. PubMed ID: 20203200
[TBL] [Abstract][Full Text] [Related]
39. I716F AβPP mutation associates with the deposition of oligomeric pyroglutamate amyloid-β and α-synucleinopathy with Lewy bodies.
Sieczkowski E; Milenkovic I; Venkataramani V; Giera R; Ströbel T; Höftberger R; Liberski PP; Auff E; Wirths O; Bayer TA; Kovacs GG
J Alzheimers Dis; 2015; 44(1):103-14. PubMed ID: 25182745
[TBL] [Abstract][Full Text] [Related]
40. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases.
Hannula MJ; Myöhänen TT; Tenorio-Laranga J; Männistö PT; Garcia-Horsman JA
Neuroscience; 2013 Jul; 242():140-50. PubMed ID: 23562579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
